Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

.:: Aurgalys Team ::.

Philippe Berthon, PhD

Philippe Berthon, General Partner

Chief Executive Officer – Evry-Paris France
ph.berthon@aurgalys.com

Philippe Berthon is Founder and Chief Executive Officer of Aurgalys, also board member Essonne Economy Agency. Previously, Dr Berthon was Chief Executive Officer of Vaxon-Biotech (2004-2008), a company developing cancer immunotherapeutic products at late clinical development stages.  Philippe founded UroGene in 1998, was CEO then President & CSO. UroGene was dedicated to urological diseases including cancer and incontinence, raised a total of €25M venture capital money, and was traded off to Groupe Pierre Fabre early 2005. Prior to these appointments, Dr Berthon was co-founder and CEO of CeRePP at Hospital Saint Louis, Paris, from 1995-1999; senior post-doctoral fellow at the Cancer Research Unit, University of York, UK, for 3 years; and research fellow at Paris VI University for 5 years. Dr Berthon co-authored more than 50 peer-reviewed international publications,  received his PhD in Reproduction Physiology at Paris VI University, and graduated from Challenge+ Business and Administration program, HEC School of Management, Jouy en Josas, France. Philippe Berthon is member of France Biotech, of Société Française des Analystes Financiers (SFAF) and Association des Analystes Conseil en Investissement Financier et Transmission d’Entreprises (ACIFTE).

Mickael Dubourd, PhD

Mickael Dubourd Aurgalys-1

Head of Equity Research and Investor Relations – Evry-Paris France
m.dubourd@aurgalys.com

Dr Mickael Dubourd joined Aurgalys in February 2012 as a Life Sciences and Healthcare analyst, in charge of our Euronext customers. Since 2014, Dr Dubourd is Affiliated Professor to Grenoble Business School. Previously Mickael was a postdoctoral research associate at Keck  School of Medecine, University of Southern California in Los Angeles, USA, from 2009 to 2011. Mickael received an Advanced Master in Biotechnology Management from Grenoble Graduate School of Business, France in 2012, and completed his PhD in Medical Sciences from University College Dublin, Ireland in 2009. Dr Dubourd also holds a Biological Engineering Degree from Compiègne Tech University, France (2006). Mickael Dubourd is member of Société Française des Analystes Financiers (SFAF) and of Commission des Analystes Financiers Indépendants (COMAFI).

Christophe Dombu, PhD

Analyst – Evry-Paris France
c.dombu@aurgalys.com

Dr. Christophe Dombu joined Aurgalys in January 2014 as a Life Sciences and Healthcare analyst. Christophe holds an advanced Master degree in Pharma/ Biotech management from Grenoble Graduate School of Business. Prior to that Christophe completed a PhD in 2012, in Nanomedicine at University of Lille 2. As a researcher, Christophe participated in several nanomedicine projects with potential application in oncology, metabolic diseases and vaccines.  The diabetes project was awarded an OSEO (now Bpifrance) prize for entrepreneurship. Christophe Dombu is a member of Société Française des Analystes Financiers (SFAF).

Jamila El Bougrini, PhD

Analyst – Evry-Paris France
j.elbougrini@aurgalys.com

Dr. Jamila El Bougrini joined Aurgalys in May 2015 as a Financial analyst dedicated to Life Sciences and Healthcare companies. Jamila obtained her PhD in Cellular and Molecular Biology in 2009 from University Paris XI and worked during 4 years in French institutions such as « Fondation ARC pour la recherche sur le cancer » and « Vaincre la mucoviscidose » as a scientific officer. She had the opportunity to work within European networks, and to lead several projects and calls for oncology and cystic fibrosis programs. In 2015, she completed her scientific background by an MBA in International Management from University Paris Dauphine and IAE Paris-Sorbonne.